Delivery of Peptide Nucleic Acids Using an Argininocalix[4]arene as Vector.
Calixarene amphiphiles
Calixarenes
Cell transfection
Delivery
MicroRNAs
Non-viral vectors
Peptide nucleic acids
miRNA therapeutics
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
31
3
2021
Statut:
ppublish
Résumé
The importance of peptide nucleic acids (PNAs) for alteration of gene expression is nowadays firmly established. PNAs are characterized by a pseudo-peptide backbone composed of N-(2-aminoethyl)glycine units and have been found to be excellent candidates for antisense and antigene therapies. Recently, PNAs have been demonstrated to alter the action of microRNAs and thus can be considered very important tools for miRNA therapeutics. In fact, the pharmacological modulation of microRNA activity appears to be a very interesting approach in the development of new types of drugs. Among the limits of PNAs in applied molecular biology, the delivery to target cells and tissues is of key importance. The aim of this chapter is to describe methods for the efficient delivery of unmodified PNAs designed to target microRNAs involved in cancer, using as model system miR-221-3p and human glioma cells as in vitro experimental cellular system. The methods employed to deliver PNAs targeting miR-221-3p here presented are based on a macrocyclic multivalent tetraargininocalix[4]arene used as non-covalent vector for anti-miR-221-3p PNAs. High delivery efficiency, low cytotoxicity, maintenance of the PNA biological activity, and easy preparation makes this vector a candidate for a universal delivery system for this class of nucleic acid analogs.
Identifiants
pubmed: 33336275
doi: 10.1007/978-1-0716-0943-9_10
doi:
Substances chimiques
Drug Carriers
0
MicroRNAs
0
Peptide Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-143Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
He L, Hannon GJ (2010) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531
Griffiths-Jones S (2004) The microRNA registry. Nucleic Acids Res 32:D109–D111
pubmed: 14681370
pmcid: 308757
Monga I, Kumar M (2019) Computational resources for prediction and analysis of functional miRNA and their targetome. Methods Mol Biol 1912:215–250
pubmed: 30635896
Lim LP, Lau NC, Garrett-Engele P et al (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769–773
pubmed: 15685193
Filipowicz W, Jaskiewicz L, Kolb FA et al (2005) Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15:331–341
pubmed: 15925505
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S et al (2019) An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 234:5451–5465
pubmed: 30471116
Laina A, Gatsiou A, Georgiopoulos G et al (2018) RNA therapeutics in cardiovascular precision medicine. Front Physiol 9:953
pubmed: 30090066
pmcid: 6068259
Bardin P, Sonneville F, Corvol H et al (2018) Emerging microRNA therapeutic approaches for cystic fibrosis. Front Pharmacol 9:1113
pubmed: 30349480
pmcid: 6186820
Finotti A, Fabbri E, Lampronti I et al (2019) MicroRNAs and long non-coding RNAs in genetic diseases. Mol Diagn Ther 23:155–171
pubmed: 30610665
pmcid: 6469593
Lima JF, Cerqueira L, Figueiredo C et al (2018) Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol 15:338–352
pubmed: 29570036
pmcid: 5927725
Kwok GT, Zhao JT, Weiss J et al (2017) Translational applications of microRNAs in cancer, and therapeutic implications. Noncoding RNA Res 2:143–150
pubmed: 30159433
pmcid: 6084838
Li Y, Wang Y, Shen X, Han X (2019) miR-128 functions as an oncomiR for the downregulation of HIC1 in breast cancer. Front Pharmacol 10:1202
pubmed: 31680974
pmcid: 6811662
Kim J, Siverly AN, Chen D et al (2016) Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways. Cancer Res 76:6424–6435
pubmed: 27569213
pmcid: 5093036
Gambari R, Brognara E, Spandidos DA et al (2016) Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol 49:5–32
pubmed: 27175518
pmcid: 4902075
Elhefnawi M, Salah Z, Soliman B (2019) The promise of miRNA replacement therapy for hepatocellular carcinoma. Curr Gene Ther 9:290–304
Gambari R (2014) Peptide nucleic acids: a review on recent patents and technology transfer. Expert Opin Ther Pat 24:267–294
pubmed: 24405414
Nielsen PE, Egholm M, Berg RH et al (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497–1500
pubmed: 1962210
Demidov VV, Potaman VN, Frank-Kamenetskii MD et al (1994) Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol 48:1310–1313
pubmed: 7945427
Nielsen PE (2001) Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 8:545–550
pubmed: 11281841
Egholm M, Buchardt O, Christensen L et al (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365:566–568
pubmed: 7692304
Nielsen PE (2010) Gene targeting and expression modulation by peptide nucleic acids (PNA). Curr Pharm Des 16:3118–3123
pubmed: 20687874
Tonelli R, McIntyre A, Camerin C et al. (2012) Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 18:796–807
Gambari R (2001) Peptide nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des 7:1839–1862
pubmed: 11562312
Montagner G, Bezzerri V, Cabrini G et al (2017) An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. Int J Biol Macromol 99:492–498
pubmed: 28167114
Cheng CJ, Bahal R, Babar IA et al (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518:107–110
pubmed: 25409146
Gupta A, Quijano E, Liu Y et al (2017) Anti-tumor activity of miniPEG-γ-modified PNAs to inhibit microRNA-210 for cancer therapy. Mol Ther Nucleic Acids 9:111–119
pubmed: 29246289
pmcid: 5633812
Quijano E, Bahal R, Ricciardi A et al (2017) Therapeutic peptide nucleic acids: principles, limitations, and opportunities. Yale J Biol Med 90:583–598
pubmed: 29259523
pmcid: 5733847
Manicardi A, Gambari R, de Cola L et al (2018) Preparation of anti-miR PNAs for drug development and nanomedicine. Methods Mol Biol 1811:49–63
pubmed: 29926445
Fabbri E, Tamanini A, Jakova T et al (2017) A peptide nucleic acid against microRNA miR-145-5p enhances the expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in Calu-3 cells. Molecules 23:71
pmcid: 6017273
Mercurio S, Cauteruccio S, Manenti R et al (2019) miR-7 knockdown by peptide nucleic acids in the ascidian Ciona intestinalis. Int J Mol Sci 20:5127
pmcid: 6829576
Seo YE, Suh HW, Bahal R et al (2019) Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 201:87–98
pubmed: 30802686
pmcid: 6451656
Sajadimajd S, Yazdanparast R, Akram S (2016) Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells. Tumour Biol 37:5413–5426
pubmed: 26563369
Amato F, Tomaiuolo R, Nici F et al (2014) Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. Biomed Res Int 2014:610718
pubmed: 24829907
pmcid: 4009323
Milani R, Brognara E, Fabbri E et al (2019) Targeting miR-155-5p and miR-221-3p by peptide nucleic acids induces caspase-3 activation and apoptosis in temozolomide-resistant T98G glioma cells. Int J Oncol 55:59–68
pubmed: 31180529
pmcid: 6561624
Rasmussen FW, Bendifallah N, Zachar V et al (2006) Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides 16:43–57
pubmed: 16584294
Cortesi R, Mischiati C, Borgatti M et al (2004) Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles. AAPS PharmSci 6:10–21
Nastruzzi C, Cortesi R, Esposito E et al (2000) Liposomes as carriers for DNA-PNA hybrids. J Control Release 68:237–249
pubmed: 10925132
Ringhieri P, Avitabile C, Saviano M et al (2016) The influence of liposomal formulation on the incorporation and retention of PNA oligomers. Colloids Surf B Biointerfaces 145:462–469
pubmed: 27236097
Chiarantini L, Cerasi A, Millo E et al (2005) Antisense peptide nucleic acid delivered by core-shell microspheres. J Control Release 101:397–398
pubmed: 15822234
Mischiati C, Sereni A, Finotti A et al (2004) Complexation to cationic microspheres of double-stranded peptide nucleic acid-DNA chimeras exhibiting decoy activity. J Biomed Sci 11:697–704
pubmed: 15316146
Chiarantini L, Cerasi A, Millo E et al (2006) Enhanced antisense effect of modified PNAs delivered through functional PMMA microspheres. Int J Pharm 324:83–91
pubmed: 16926075
Albertshofer K, Siwkowski AM, Wancewicz EV et al (2005) Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. J Med Chem 48:6741–6749
pubmed: 16220989
Kaihatsu K, Huffman KE, Corey DR (2004) Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. Biochemistry 43:14340–14347
pubmed: 15533038
Fabbri E, Manicardi A, Tedeschi T et al (2011) Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem 6:2192–2202
pubmed: 22012891
Torres AG, Threlfall RN, Gait MJ (2011) Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2′-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA 3:71–78
Brognara E, Fabbri E, Bazzoli E et al (2014) Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. J Neuro-Oncol 118:19–28
Brognara E, Fabbri E, Bianchi N et al (2014) Molecular methods for validation of the biological activity of peptide nucleic acids targeting microRNAs. Methods Mol Biol 1095:165–176
pubmed: 24166312
Brognara E, Fabbri E, Montagner G et al (2016) High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222. Int J Oncol 48:1029–1038
pubmed: 26708164
Shiraishi T, Nielsen PE (2006) Enhanced delivery of cell-penetrating peptide-peptide nucleic acid conjugates by endosomal disruption. Nat Protoc 1:633–636
pubmed: 17406290
Ghavami M, Shiraishi T, Nielsen PE (2019) Cooperative cellular uptake and activity of octaarginine antisense peptide nucleic acid (PNA) conjugates. Biomol Ther 9:554
Soudah T, Khawaled S, Aqeilan RI et al (2019) AntimiR-155 cyclic peptide-PNA conjugate: synthesis, cellular uptake, and biological activity. ACS Omega 4:13954–13961
pubmed: 31497713
pmcid: 6714607
Brognara E, Fabbri E, Aimi F et al (2012) Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41:2119–2127
pubmed: 22992757
Manicardi A, Fabbri E, Tedeschi T et al (2012) Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells. Chembiochem 13:1327–1337
pubmed: 22639449
pmcid: 3401907
Verona MD, Verdolino V, Palazzesi F et al (2017) Focus on pna flexibility and rna binding using molecular dynamics and metadynamics. Sci Rep 7:42799
pubmed: 28211525
pmcid: 5314342
Liu C, Wang J, Huang S et al (2018) Self-assembled nanoparticles for cellular delivery of peptide nucleic acid using amphiphilic N,N,N-trimethyl-O-alkyl chitosan derivatives. J Mater Sci Mater Med 29:114
pubmed: 30019119
Borgatti M, Breda L, Cortesi R et al (2002) Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. Biochem Pharmacol 64:609–616
pubmed: 12167479
Beavers KR, Werfel TA, Shen T et al (2016) Porous silicon and polymer nanocomposites for delivery of peptide nucleic acids as anti-microRNA therapies. Adv Mater 28:7984–7992
pubmed: 27383910
pmcid: 5152671
Bertucci A, Prasetyanto EA, Septiadi D et al (2015) Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small 11:5687–5695
pubmed: 26395266
Sansone F, Dudič M, Donofrio G et al (2006) DNA condensation and cell transfection properties of guanidinium calixarenes: dependence on macrocycle lipophilicity, size, and conformation. J Am Chem Soc 128:14528–14536
pubmed: 17090036
Bagnacani V, Franceschi V, Fantuzzi L et al (2012) Lower rim guanidinocalix[4]arenes: macrocyclic nonviral vectors for cell transfection. Bioconjug Chem 23:993–1002
pubmed: 22463059
Bagnacani V, Franceschi V, Bassi M et al (2013) Arginine clustering on calix[4]arene macrocycles for improved cell penetration and DNA delivery. Nat Commun 4:1721
pubmed: 23591888
pmcid: 3644092
Gasparello J, Lomazzi M, Papi C et al (2019) Efficient delivery of microRNA (miRNA) and anti-miRNA molecules using an argininocalix[4]arene macrocycle. Mol Ther Nucleic Acids 18:748–763
pubmed: 31733592
pmcid: 6859282
Gasparello J, Manicardi A, Casnati A et al (2019) Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene. Sci Rep 9:3036
pubmed: 30816154
pmcid: 6395679
Cao X, Gu Y, Jiang L et al (2013) A new approach to screening cancer stem cells from the U251 human glioma cell line based on cell growth state. Oncol Rep 29:1013–1018
pubmed: 23258424
Zhang C, Zhang J, Zhang A et al (2010) PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 37:1621–1626
pubmed: 21042732
Xie J, Wen JT, Xue XJ et al (2018) MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3. Eur Rev Med Pharmacol Sci 22:1914–1921
pubmed: 29687843
Zhou QY, Peng PL, Xu YH (2019) MiR-221 affects proliferation and apoptosis of gastric cancer cells through targeting SOCS3. Eur Rev Med Pharmacol Sci 23:9427–9435
pubmed: 31773681
Ergun S, Arman K, Temiz E et al (2014) Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines. Mol Biol Rep 41:5877–5881
pubmed: 24969479
Hu XH, Zhao ZX, Dai J et al (2019) MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27. J Cell Biochem 120:4665–4674
pubmed: 30582227
Xie X, Huang Y, Chen L et al (2018) miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF. Oncol Lett 16:6697–6704
pubmed: 30405811
pmcid: 6202478
Gramantieri L, Fornari F, Ferracin M et al (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 15:5073–5081
pubmed: 19671867
pmcid: 3900721
Yang Y, Cui H, Wang X (2019) Downregulation of EIF5A2 by miR-221-3p inhibits cell proliferation, promotes cell cycle arrest and apoptosis in medulloblastoma cells. Biosci Biotechnol Biochem 83:400–408
pubmed: 30551723
Kenis PJA, Noordman OFJ, Schonherr H et al (1998) Supramolecular materials: molecular packing of tetranitrotetrapropoxycalix[4]arene in highly stable films with second-order nonlinear optical properties. Chem Eur J 4:1225–1234
Torres AG, Fabani MM, Vigorito E, Gait MJ (2011) MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA 17:933–943
pubmed: 21441346
pmcid: 3078742